GGrantIndex
Sort

48,018 grants matching immunotherapy

Novel Approaches to Targeting Cancers Associated with VHL Mutations

$630,437
Ramaprasad Srinivasan · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA

AN INTEGRATED PLATFORM FOR NOVEL PERSONALIZED LIVER CANCER THERAPEUTICS

$630,404
Ernesto Guccione · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · CA

Exercise as an Immune Adjuvant for Gamma Delta T-cell Therapies in Hematologic Malignancies

$630,238
Richard J Simpson · University Of Arizona · R01 · FY2025 · CA

Lung Cancer Early Detection and Immunotherapy Response Prediction and Monitoring with an Exo-PROS Liquid Biopsy Assay

$630,231
Yun Wu · State University Of New York At Buffalo · R01 · FY2023 · CA

Heterlogous Prime and Boost Vaccine Strategies

$630,187
Jonathan Smith · Duke University · P01 · FY2007 · CA

Developing an Oncology Workforce for the 21st Century

$630,175
Olufunmilayo I Olopade · University Of Chicago · K12 · FY2021 · CA

Shark Radiotherapy for the Treatment of Triple-Negative Breast Cancer

$630,171
Aaron Matthew Lebeau · University Of Wisconsin-Madison · R01 · FY2025 · CA

Co-Clinical Research Resource for Imaging Tumor Associated Macrophages

$630,142
Heike Elizabeth Daldrup-Link · Stanford University · U24 · FY2022 · CA

Comparative Modeling for the Prevention and Control of Uterine Cancer

$630,059
Jason Wright · Columbia University Health Sciences · U01 · FY2025 · CA

Advancing RAS pathway targeted therapy in NF1-MPNST: effects of SHP2 and CDK4/6 inhibitors on the tumor and the tumor immune microenvironment

$630,037
Christine Anne Pratilas · Johns Hopkins University · R01 · FY2025 · CA

Epigenetic control of Foxp3 expression in induced T regulatory cells

$630,000
Anjana Rao · La Jolla Institute For Immunology · R01 · FY2018 · AI

Multiplexed drug testing of micro-dissected tumors using a microfluidic platform with integrated electrochemical aptasensors

$629,966
Albert Folch · University Of Washington · R01 · FY2024 · CA

Synergized Immune and Tumor Cell Bone Marrow Biomarkers to Predict Recurrence in Triple Negative Breast Cancer

$629,761
Rebecca L Aft · Washington University · R01 · FY2021 · CA

Adoptive Transfer of MART-1 TCR Engineered Cells after a Myelodepleting Regimen

$629,729
Antoni Ribas · California Institute Of Technology · P01 · FY2013 · CA

Predict radiation-induced shifts in patient-specific tumor immune ecosystem composition to harness immunological consequences of radiotherapy

$629,676
Heiko Enderling · H. Lee Moffitt Cancer Ctr & Res Inst · U01 · FY2021 · CA

Targeting the transcriptional and epigenetic landscape in chemo-refractory Small-Cell Lung Cancer

$629,612
Kwok Kin Wong · New York University School Of Medicine · U01 · FY2020 · CA

UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT

$629,550
Kevin J Cullen · University Of Maryland Baltimore · P30 · FY2020 · CA

UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT

$629,550
Kevin J Cullen · University Of Maryland Baltimore · P30 · FY2018 · CA

UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT

$629,550
Kevin J Cullen · University Of Maryland Baltimore · P30 · FY2017 · CA

UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT

$629,550
Kevin J Cullen · University Of Maryland Baltimore · P30 · FY2019 · CA

Regulatory T Cell Function in Ovarian Cancer

$629,546
Kirsten B Moysich · Roswell Park Cancer Institute Corp · R01 · FY2010 · CA

Personalized vaccine immunotherapy in combination with anti-PD 1 antibody for recurrent or metastatic squamous cell carcinoma of the head and neck

$629,482
Dong Moon Shin · Emory University · R01 · FY2025 · CA

Advancing treatment outcomes in malignant glioma by integrating immunotherapy and standard of care using genetically engineered mice that recapitulate molecular feature of human glioma

$629,475
Alain Charest · Beth Israel Deaconess Medical Center · R01 · FY2019 · CA

Humoral Immune Mechanisms of Acute and Chronic Neurologic Sequelae of COVID-19

$629,459
Michael R Wilson · University Of California, San Francisco · R01 · FY2023 · NS

T-cell intrinsic mechanisms of resistance to PD-1 checkpoint blockade

$629,441
Michelle Krogsgaard · New York University School Of Medicine · R01 · FY2022 · CA